Long QT SyndromeNCT05348564
Comparing Direct vs Indirect Methods for Cascade Screening
A study testing Direct contact of family members for cascade screening of relevant variants in people with Long QT Syndrome and Familial Hypercholesterolemia, run by University of Maryland, Baltimore at 1 site in United States.
Trial summary
An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Long QT Syndrome, Familial Hypercholesterolemia, Ethics
- What is being tested?
- Direct contact of family members for cascade screening of relevant variants
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 15 May 2023to Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Proband Inclusion Criteria:
- KCNQ1 Thr224Met or APOB R3527Q carrier
- 18 years or older
Proband Exclusion Criteria:
- None
Family Inclusion Criteria:
- 1st degree relative of a KCNQ1 Thr224Met or APOB Arg3527Gln carrier
Family Exclusion Criteria:
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Maryland Amish Research Clinic
Lancaster, Pennsylvania, 17602
Susan Shaub, RN, 7173924948, sshaub@som.umaryland.edu
About this study
Official title: Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)
An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes.
Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.
Read the detailed description
Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.
Aim 1:
Aim 1 will assess efficacy of the approaches on uptake of cascade screening. The primary outcome will assess uptake of cascade screening among all first-degree relatives of the probands. We will compare the proportion first-degree relatives who undergo screening out of all eligible relatives in the direct vs indirect arms of the study. Secondary outcomes will asses rate of detection of new cases among all first degree family members. We will have good power to detect a clinically meaningful difference of 15% between he direct and indirect arms of the study.
These cascade screening efficacy endpoints address the question of whether contacting family members for probands improves the uptake of testing among family members.
Aim 2:
Aim 2 will assess patient-centered outcomes in both probands and family members that address how the intervention of direct contact of family members impacts participants' mental, physical, or psychosocial outcomes. For this aim surveys will be given to the probands and family members approximately one week after contact of family members has occurred and at the end of the study. The secondary outcomes associated with this aim include: perceived alignment of ethical principles, anxiety regarding method of contact, perceived pressure to undergo testing (family members only), and knowledge of disease. We will also assess health behaviors such as taking recommended preventative medications (beta-blockers and statins), lifestyle modifications, and seeing health care providers. These outcomes will be assessed by validated and study-created surveys assessed 1-week post implementation and at the end of study.
These patient-centered outcomes assess the extent to which the intervention allows for autonomous decision making and is associated with acceptable psychosocial outcomes.
Aim 3:
Aim 3 will perform qualitative assessments of the intervention to evaluate implementation outcomes in the direct vs indirect arms of the study. We will include interviews among 15 probands randomized to the direct arm, 15 probands randomized to the indirect arm, 15 family members who undergo cascade screening from the direct arm (carriers and non-carriers), 15 family members who undergo cascade screening from the indirect arm (carriers and non-carriers), and 15 family members who decline cascade testing (from direct arm and from indirect arm but informed by a proband, thus allowing us to invite them to participate). We will also interview study staff to understand facilitators and challenges across patient and organizational factors.
Implementation reach, dosage, and fidelity will be based on proportions and means/standard deviations for relevant quantitative variables (e.g., number of genetic counseling visits scheduled and completed). Outreach approach's acceptability, barriers, and facilitators will be based on descriptive analyses using interview data. Data analyses will be based on a codebook, consensus coding and consensus narrative Qualitative interviews will be transcribed verbatim and analyzed using NVivo 11.0. The research team will conduct standard content analysis and systematic comparison of data between the two intervention groups; acceptability, appropriateness, patterns in facilitators/barriers, implementation quality, and early sustainment.
In sum, these interviews will provide more in-depth understanding of the ethical implications of our intervention and evaluation of the implementation process by relevant stakeholders.
- Being tested
- Direct contact of family members for cascade screening of relevant variants
- Medical subject headings
- Long QT Syndrome, Hyperlipoproteinemia Type II
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Direct contact of family members for cascade screening of relevant variantsBehavioural
Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
| Study group | Role | What they receive |
|---|---|---|
| Direct contact | Experimental | Study team contact of family members Receives: Behavioral: Direct contact of family members for cascade screening of relevant variants |
| Indirect contact | No intervention | Proband initiated contact of family members |
What is being measured
The primary outcome is the main question the study is designed to answer.
Uptake of cascade screening among all first-degree relatives
Proportion of first-degree relatives who undergo testing/All eligible first-degree relatives
Measured: Through study completion: approximately 4 years
Secondary outcomes (5)
Number of new cases detected among all first-degree family members
New cases/All eligible first-degree family members
Measured: Through study completion: approximately 4 years
Perceived alignment of ethical principles questionnaire
Among probands and family members
Measured: up to 6 months
Anxiety regarding method of contact questionnaire
Among probands and family members
Measured: up to 6 months
Perceived pressure to undergo testing/share health information questionnaire
Among probands and family members
Measured: up to 6 months
Knowledge of disease and variant questionnaire
Among probands and family members
Measured: up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2022
- Study start15 May 2023
- Primary completionOct 2026 (estimated)
- Study completionOct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long QT SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Maryland, Baltimore
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amber Beitelshees, University of Maryland, Baltimore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05348564
- Sponsor's protocol ID
- R01HL163514
- Status last verified
- Apr 2026
- First submitted
- 4 Apr 2022
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)
- ClinicalTrials.gov ID
- NCT05348564
- Acronym / sponsor ID
- R01HL163514
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of Maryland, BaltimoreUniversity, hospital or other
- Study start
- 15 May 2023 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Oct 2027 (estimated)
- First posted
- 27 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes.
Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.
Detailed description
Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.
Aim 1:
Aim 1 will assess efficacy of the approaches on uptake of cascade screening. The primary outcome will assess uptake of cascade screening among all first-degree relatives of the probands. We will compare the proportion first-degree relatives who undergo screening out of all eligible relatives in the direct vs indirect arms of the study. Secondary outcomes will asses rate of detection of new cases among all first degree family members. We will have good power to detect a clinically meaningful difference of 15% between he direct and indirect arms of the study.
These cascade screening efficacy endpoints address the question of whether contacting family members for probands improves the uptake of testing among family members.
Aim 2:
Aim 2 will assess patient-centered outcomes in both probands and family members that address how the intervention of direct contact of family members impacts participants' mental, physical, or psychosocial outcomes. For this aim surveys will be given to the probands and family members approximately one week after contact of family members has occurred and at the end of the study. The secondary outcomes associated with this aim include: perceived alignment of ethical principles, anxiety regarding method of contact, perceived pressure to undergo testing (family members only), and knowledge of disease. We will also assess health behaviors such as taking recommended preventative medications (beta-blockers and statins), lifestyle modifications, and seeing health care providers. These outcomes will be assessed by validated and study-created surveys assessed 1-week post implementation and at the end of study.
These patient-centered outcomes assess the extent to which the intervention allows for autonomous decision making and is associated with acceptable psychosocial outcomes.
Aim 3:
Aim 3 will perform qualitative assessments of the intervention to evaluate implementation outcomes in the direct vs indirect arms of the study. We will include interviews among 15 probands randomized to the direct arm, 15 probands randomized to the indirect arm, 15 family members who undergo cascade screening from the direct arm (carriers and non-carriers), 15 family members who undergo cascade screening from the indirect arm (carriers and non-carriers), and 15 family members who decline cascade testing (from direct arm and from indirect arm but informed by a proband, thus allowing us to invite them to participate). We will also interview study staff to understand facilitators and challenges across patient and organizational factors.
Implementation reach, dosage, and fidelity will be based on proportions and means/standard deviations for relevant quantitative variables (e.g., number of genetic counseling visits scheduled and completed). Outreach approach's acceptability, barriers, and facilitators will be based on descriptive analyses using interview data. Data analyses will be based on a codebook, consensus coding and consensus narrative Qualitative interviews will be transcribed verbatim and analyzed using NVivo 11.0. The research team will conduct standard content analysis and systematic comparison of data between the two intervention groups; acceptability, appropriateness, patterns in facilitators/barriers, implementation quality, and early sustainment.
In sum, these interviews will provide more in-depth understanding of the ethical implications of our intervention and evaluation of the implementation process by relevant stakeholders.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Direct contact | Experimental | Behavioral: Direct contact of family members for cascade screening of relevant variantsStudy team contact of family members |
| Indirect contact | No intervention | –Proband initiated contact of family members |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Direct contact of family members for cascade screening of relevant variantsStudy team members will directly contact potentially impacted family members to offer genetic testing of relevant variant. | Behavioural | Direct contact |
Primary outcome
Uptake of cascade screening among all first-degree relatives
Time frame: Through study completion: approximately 4 years
Proportion of first-degree relatives who undergo testing/All eligible first-degree relatives
5 secondary outcomes
Number of new cases detected among all first-degree family members
Time frame: Through study completion: approximately 4 years
Perceived alignment of ethical principles questionnaire
Time frame: up to 6 months
Anxiety regarding method of contact questionnaire
Time frame: up to 6 months
Perceived pressure to undergo testing/share health information questionnaire
Time frame: up to 6 months
Knowledge of disease and variant questionnaire
Time frame: up to 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Long QT Syndrome
Active, not recruitingObservational study
Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3
Long QT Syndrome Type 3, Long QT Syndrome 2
Not yet recruitingObservational study
Physical Activity and Functional Capacity in Patients With Congenital Long QT Syndrome
Long QT Syndrome, Channelopathies
Recruiting
Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders
ICSI, IVF
RecruitingPhase 1/2
Opt-IVF for Personalized Medicine for Normal Responders
Ivf
RecruitingPhase 2/3
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
Long QT Syndrome (LQTS) 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Direct contact of family members for cascade screening of relevant variants in people with Long QT Syndrome and Familial Hypercholesterolemia, run by University of Maryland, Baltimore at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amber L Beitelshees, PharmD (410-706-0118, abeitels@som.umaryland.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Uptake of cascade screening among all first-degree relatives (time frame: Through study completion: approximately 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.